Minneapolis Clinical Trials
Formulation Study
Participate in a clinical study as a potential new anti-cancer drug, called elraglusib.
3-separate inpatient stays of 3 nights nights
10 visits
Purpose: to evaluate the safety, tolerability and how the body processes an investigational medication of an anti-cancer drug, called elraglusib.
Reimbursement for study participation will be provided for time and travel of up to $5,680
This study has been reviewed by an independent ethics committee
Call 612-315-6490 to discuss your eligibility today!
Eligibility
Age: 18-55
BMI: 18-32 kg/m2
Medication: No prescription or over-the-counter medications, herbal remedies or nutritional supplements such as multivitamins within 3 days before your first dose of the study drug
Compensation: up to $5,680 for study completion
Smoking: You should not smoke more than 2 cigarettes per day (or vaping equivalent) and should be able to abstain from smoking during the confinement periods during this study.